India caps trade margins on 137 cancer drugs to curb costs

The National Pharmaceutical Pricing Authority (NPPA) has clamped down on profit margins for cancer drug distribution, approving price controls on 137 oncology medications during its meetings held on October 16 and 17. The new measure restricts trade margins—the markup charged by wholesalers and retailers—to a maximum of 30 percent across the supply chain.

Industry observers expect the cap to translate into substantial price reductions for patients, with some cancer drugs potentially becoming available at prices 70 percent lower than current levels. The move addresses concerns about affordability of life-saving oncology treatments, which have remained out of reach for many Indian households despite growing domestic pharmaceutical manufacturing capacity.

Cancer treatment costs have long been a burden on Indian patients, with many forgoing or delaying essential medications due to expense. By regulating the distribution margins rather than imposing direct price controls on manufacturers, the NPPA aims to reduce prices while maintaining industry viability and ensuring steady supply of critical medications.

The decision underscores the government's ongoing efforts to balance accessibility of essential medicines with industry sustainability. Similar margin controls have been applied to other drug categories in recent years as policymakers attempt to make healthcare more affordable across the country's population of 1.4 billion people.